Needham upgraded Gilead (GILD) to Buy from Hold with a $133 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead announces CHMP opinion recommending lenacapavir
- Gilead and Arcus Biosciences’ Promising Lung Cancer Study: Market Implications
- Gilead Sciences Advances HIV Prevention with New Clinical Study
- Positive Outlook for Gilead Sciences Amid Strong HIV and Veklury Performance
- Gilead and Arcus Biosciences’ Promising Phase 3 Lung Cancer Study Update